Beta
ManageSearchChatDiscover
8658

Sildenafil Citrate and Uteroplacental Perfusion in Fetal Growth Restriction

Article

Last updated: 03 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero.
Objective: To evaluate effectiveness and safety of Sildenafil citrate for treatment of intrauterine growth restriction (IUGR). Design: A prospective randomized control study.
Setting: At Ain shams University hospital and Kafr Aldwwar main Hospital in El-Beheria governorate. Subjects: Eighty pregnant women with gestational age between 24 and 34 weeks having singleton pregnancy and suffering from IUGR attending an antenatal clinic.
Methods: Eighty pregnant women with FGR and abnormal umbilical artery Doppler between 24and34 weeks were randomly allocated to sildenafil (n= 40) 25mg tid or placebo (n=40) with a plenty of fluids until delivery. Main outcome measure: Length of pregnancy, neonatal weight and ICU admission.
Results: Sildenafil treatment was associated with a significant increase in length of pregnancy (P> 0.05) and a significant increase in estimated fetal weight by ultrasound (P<0.05), and was associated with a significant decrease in neonatal ICU admission (P=0.218) and neonatal mortality (P=0.290).
Conclusion: Sildenafil citrate can improve utero-placental perfusion and length of pregnancy in pregnancies complicated by IUGR. It appears to have a significantly positive effect on fetal weight. Sildenafil treatment may offer a new opportunity to improve perinatal outcomes, for pregnancies complicated by IUGR. However these observations require further studies on wide scale.

Keywords

Sildenafil citrate, Uteroplacental Perfusion, fetal growth restriction

Authors

First Name

Amr Hasan

Last Name

El-Shalakany

MiddleName

-

Affiliation

Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University

Email

-

City

-

Orcid

-

First Name

Mohamed Mahmoud

Last Name

Abd El Aleem

MiddleName

-

Affiliation

Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University

Email

-

City

-

Orcid

-

First Name

Mohamed Zaifer Ali

Last Name

Bawady

MiddleName

-

Affiliation

Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University

Email

bawady2010@yahoo.com

City

-

Orcid

-

Volume

71

Article Issue

4

Related Issue

1654

Issue Date

2018-04-01

Receive Date

2018-03-20

Publish Date

2018-04-01

Page Start

2,989

Page End

2,995

Print ISSN

1687-2002

Online ISSN

2090-7125

Article File

EJHM_Volume 71_Issue 4_Pages 2989-2995.pdf

PDF . 396.8kB

Link

https://ejhm.journals.ekb.eg/article_8658.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=8658

Order

19

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Sildenafil Citrate and Uteroplacental Perfusion in Fetal Growth Restriction

Details

Type

Article

Created At

22 Jan 2023